Janus Henderson Global Life Sciences Fund
Fund
JFNCX
Price as of:
$62.87
- $1.81
- 2.80%
Primary Theme
fund company
Name
As of 11/15/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
6.5%
1 yr return
18.6%
3 Yr Avg Return
3.0%
5 Yr Avg Return
9.1%
Net Assets
$5.23 B
Holdings in Top 10
42.5%
52 WEEK LOW AND HIGH
$64.7
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 1.76%
SALES FEES
Front Load N/A
Deferred Load 1.00%
TRADING FEES
Turnover 32.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$2,500
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 11/15/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
JFNCX - Profile
Distributions
- YTD Total Return 6.5%
- 3 Yr Annualized Total Return 3.0%
- 5 Yr Annualized Total Return 9.1%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.61%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameJanus Henderson Global Life Sciences Fund
-
Fund Family NameJanus Henderson
-
Inception DateJul 06, 2009
-
Shares OutstandingN/A
-
Share ClassC
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerAndrew Acker
JFNCX - Performance
Return Ranking - Trailing
| Period | JFNCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 6.5% | -26.5% | 26.6% | 27.67% |
| 1 Yr | 18.6% | -9.4% | 55.1% | 26.42% |
| 3 Yr | 3.0%* | -30.3% | 9.4% | 15.13% |
| 5 Yr | 9.1%* | -6.2% | 14.0% | 19.86% |
| 10 Yr | 8.7%* | 0.4% | 13.2% | 20.72% |
* Annualized
Return Ranking - Calendar
| Period | JFNCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 1.3% | -12.6% | 19.0% | 63.52% |
| 2022 | -3.5% | -53.9% | 3.2% | 8.55% |
| 2021 | -4.2% | -39.6% | 24.2% | 67.76% |
| 2020 | 15.2% | -13.6% | 178.2% | 40.94% |
| 2019 | 20.6% | 3.8% | 63.8% | 52.63% |
Total Return Ranking - Trailing
| Period | JFNCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 6.5% | -26.5% | 26.6% | 27.67% |
| 1 Yr | 18.6% | -9.4% | 55.1% | 26.42% |
| 3 Yr | 3.0%* | -30.3% | 9.4% | 15.13% |
| 5 Yr | 9.1%* | -6.2% | 14.0% | 19.86% |
| 10 Yr | 8.7%* | 0.4% | 13.2% | 20.72% |
* Annualized
Total Return Ranking - Calendar
| Period | JFNCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 6.5% | -12.6% | 19.0% | 28.30% |
| 2022 | -3.5% | -53.9% | 3.7% | 17.11% |
| 2021 | 5.9% | -33.9% | 26.0% | 66.45% |
| 2020 | 24.5% | -0.7% | 180.6% | 42.28% |
| 2019 | 28.1% | 4.6% | 63.8% | 41.35% |
NAV & Total Return History
JFNCX - Holdings
Concentration Analysis
| JFNCX | Category Low | Category High | JFNCX % Rank | |
|---|---|---|---|---|
| Net Assets | 5.23 B | 6.87 M | 47.2 B | 11.32% |
| Number of Holdings | 117 | 26 | 430 | 17.61% |
| Net Assets in Top 10 | 2.33 B | 2.12 M | 22.1 B | 16.35% |
| Weighting of Top 10 | 42.50% | 18.4% | 79.7% | 67.92% |
Top 10 Holdings
- Eli Lilly Co. COM NPV 9.37%
- UnitedHealth Group Inc. COM USD0.01 6.13%
- Novo Nordisk A/S SER'B'DKK0.1 5.95%
- AstraZeneca PLC ORD USD0.25 3.76%
- AbbVie Inc. COM USD0.01 3.68%
- Merck Co., Inc COM USD0.50 3.28%
- Amgen Inc. COM USD0.0001 3.11%
- Sanofi EUR2 2.45%
- Boston Scientific Corporation COM USD0.01 2.42%
- Vertex Pharmaceuticals Incorporated COM USD0.01 2.35%
Asset Allocation
| Weighting | Return Low | Return High | JFNCX % Rank | |
|---|---|---|---|---|
| Stocks | 90.97% | 87.34% | 106.13% | 93.08% |
| Preferred Stocks | 2.07% | 0.00% | 7.86% | 8.18% |
| Bonds | 0.29% | 0.00% | 12.39% | 8.81% |
| Convertible Bonds | 0.13% | 0.00% | 0.37% | 3.90% |
| Cash | 0.08% | 0.00% | 33.01% | 94.34% |
| Other | 0.00% | -22.99% | 23.24% | 45.91% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | JFNCX % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 5.84% |
| Utilities | 0.00% | 0.00% | 0.00% | 10.39% |
| Technology | 0.00% | 0.00% | 22.69% | 17.53% |
| Real Estate | 0.00% | 0.00% | 5.89% | 14.29% |
| Industrials | 0.00% | 0.00% | 7.02% | 16.23% |
| Financial Services | 0.00% | 0.00% | 1.60% | 35.06% |
| Energy | 0.00% | 0.00% | 0.00% | 10.39% |
| Communication Services | 0.00% | 0.00% | 9.11% | 13.64% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 19.48% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 16.23% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 40.26% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | JFNCX % Rank | |
|---|---|---|---|---|
| US | 77.86% | 66.06% | 104.41% | 81.13% |
| Non US | 13.11% | 0.00% | 28.87% | 22.01% |
Bond Sector Breakdown
| Weighting | Return Low | Return High | JFNCX % Rank | |
|---|---|---|---|---|
| Corporate | 13.28% | 0.00% | 81.57% | 14.49% |
| Cash & Equivalents | 0.03% | 0.00% | 100.00% | 81.13% |
| Derivative | 0.00% | 0.00% | 23.24% | 29.56% |
| Securitized | 0.00% | 0.00% | 0.00% | 11.59% |
| Municipal | 0.00% | 0.00% | 0.00% | 11.59% |
| Government | 0.00% | 0.00% | 29.44% | 12.32% |
Bond Geographic Breakdown
| Weighting | Return Low | Return High | JFNCX % Rank | |
|---|---|---|---|---|
| US | 0.29% | 0.00% | 11.75% | 8.81% |
| Non US | 0.00% | 0.00% | 3.33% | 11.95% |
JFNCX - Expenses
Operational Fees
| JFNCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.76% | 0.08% | 4.48% | 22.64% |
| Management Fee | 0.64% | 0.03% | 1.25% | 38.99% |
| 12b-1 Fee | 1.00% | 0.00% | 1.00% | 76.62% |
| Administrative Fee | N/A | 0.03% | 0.25% | 47.62% |
Sales Fees
| JFNCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | 1.00% | 1.00% | 1.00% | 15.00% |
Trading Fees
| JFNCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| JFNCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 32.00% | 0.00% | 238.00% | 28.15% |
JFNCX - Distributions
Dividend Yield Analysis
| JFNCX | Category Low | Category High | JFNCX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 6.24% | 45.28% |
Dividend Distribution Analysis
| JFNCX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | SemiAnnual | Annual |
Net Income Ratio Analysis
| JFNCX | Category Low | Category High | JFNCX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.61% | -2.54% | 1.85% | 76.32% |
Capital Gain Distribution Analysis
| JFNCX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 07, 2023 | $2.852 | CapitalGainLongTerm |
| Dec 20, 2021 | $6.194 | OrdinaryDividend |
| Dec 17, 2020 | $5.030 | OrdinaryDividend |
| Dec 17, 2019 | $0.003 | OrdinaryDividend |
| Dec 17, 2019 | $3.322 | CapitalGainLongTerm |
| Dec 18, 2018 | $1.616 | CapitalGainShortTerm |
| Dec 18, 2018 | $5.107 | CapitalGainLongTerm |
| Dec 19, 2017 | $0.485 | CapitalGainLongTerm |
| Dec 19, 2016 | $0.431 | CapitalGainLongTerm |
| Dec 17, 2015 | $1.471 | CapitalGainShortTerm |
| Dec 17, 2015 | $3.133 | CapitalGainLongTerm |
| Dec 17, 2014 | $1.224 | CapitalGainShortTerm |
| Dec 17, 2014 | $4.175 | CapitalGainLongTerm |
| Dec 17, 2013 | $0.598 | CapitalGainShortTerm |
| Dec 17, 2013 | $2.841 | CapitalGainLongTerm |
| Dec 18, 2012 | $1.130 | CapitalGainLongTerm |
| Dec 22, 2010 | $0.087 | OrdinaryDividend |
JFNCX - Fund Manager Analysis
Managers
Andrew Acker
Start Date
Tenure
Tenure Rank
May 01, 2007
15.09
15.1%
"Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 23 years of financial industry experience."
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |